Additionally, those with a history of pancreatitis are carefully assessed to ensure the treatment is safe
Depending on the response, the dose may be increased to 12.5mg for weeks 17 to 20, and then to 15mg starting from week 21
There is also a trial specifically testing whether retatrutide prevents heart attacks and strokes (TRIUMPH-3, 1,800 people), and a head-to-head trial comparing retatrutide directly against tirzepatide (the active ingredient in Zepbound) under identical conditions (NCT06662383, 800 patients)
Other contraindications and precautions for GLP-1 agonists include a history of severe allergic reactions to the medication or its components, acute or chronic pancreatitis, gallbladder disease or gallstones, and certain forms of diabetic retinopathy
2018 Mar;30(3)
Markets registered the threat immediately